Demonstrates metabolic and oxidative recovery in acute kidney injury using a nanozyme approach, suggesting a novel treatment pathway.
Acute kidney injury (AKI) presents a recalcitrant pathological network where metabolic dysfunction and oxidative stress are intrinsically coupled requiring more than single-target intervention. Herein, we report the rational design of UL-Gel, a core–shell compartmentalized nanozyme–metabolic enzyme cascade microreactor for synergistic lactate depletion and reactive oxygen species scavenging. This system is constructed via enzyme-driven interfacial radical gelation, where lactate oxidase-generated H2O2 is locally relayed to the UIO-66 core to initiate polymerization, whereas elevated pathological H2O2 redirects UIO-66 toward catalase- and superoxide dismutase-like antioxidant activities. In an AKI model, UL-Gel reduced renal lactate by 69.3% and restored endogenous antioxidant enzyme activities. Transcriptomic analysis further confirmed that UL-Gel resets the renal landscape by modulating the AGE-RAGE-NOX4 and PI3K-Akt signaling axes. This work demonstrates the power of integrating dynamic nanozyme kinetics with interfacial material engineering to create smart therapeutic platforms for complex metabolic diseases.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: